Chemotherapy of lymphoma complicating immunoproliferative small intestinal disease [IPSID], the comparison of soxorubicin [DOX] -based protocols with non-dox regimens

The purpose of the present study is to compare the clinical results of different protocols in the treatment of IPSID-related lymphoma in Iran. Forty-one Iranian patients with IPSID-related lymphoma were studied retrospectively. Twenty-one patients had received a Dox-based protocol and 20 patients were treated with other regimens lacking Dox. The following results were shown in this study: The survival rate is 71.4% in the Dox group compared with 35% in the other [P<0.05 Chi-square]. The disease-free interval is 16.3 months in the Dox group compared with 11.2 in the non-Dox group [P< 0.001 unpaired student t-test]. The incidence of non-fatal complications in the two groups is slightly different but not statistically significant [0.25